Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Trastuzumab biosimilar by EirGenix for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer): Likelihood of Approval
Trastuzumab biosimilar is under clinical development by EirGenix and currently in Pre-Registration for Human Epidermal Growth Factor Receptor 2 Positive...
Trastuzumab biosimilar by Prestige BioPharma for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer): Likelihood of Approval
Trastuzumab biosimilar is under clinical development by Prestige BioPharma and currently in Phase III for Human Epidermal Growth Factor Receptor...
Trastuzumab biosimilar by Sino Biopharmaceutical for Gastric Cancer: Likelihood of Approval
Trastuzumab biosimilar is under clinical development by Sino Biopharmaceutical and currently in Phase I for Gastric Cancer. According to GlobalData,...
Trastuzumab biosimilar by Prestige BioPharma for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval
Trastuzumab biosimilar is under clinical development by Prestige BioPharma and currently in Phase III for Adenocarcinoma Of The Gastroesophageal Junction....
Trastuzumab biosimilar by Qilu Pharmaceutical for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer): Likelihood of Approval
Trastuzumab biosimilar is under clinical development by Qilu Pharmaceutical and currently in Phase III for Human Epidermal Growth Factor Receptor...
Trastuzumab biosimilar by Sino Biopharmaceutical for Metastatic Breast Cancer: Likelihood of Approval
Trastuzumab biosimilar is under clinical development by Sino Biopharmaceutical and currently in Phase I for Metastatic Breast Cancer. According to...
Trastuzumab biosimilar by Accord Healthcare for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval
Trastuzumab biosimilar is under clinical development by Accord Healthcare and currently in Pre-Registration for Adenocarcinoma Of The Gastroesophageal Junction. According...
Trastuzumab biosimilar by Accord Healthcare for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval
Trastuzumab biosimilar is under clinical development by Accord Healthcare and currently in Pre-Registration for Human Epidermal Growth Factor Receptor 2...
Trastuzumab biosimilar by Accord Healthcare for Gastric Cancer: Likelihood of Approval
Trastuzumab biosimilar is under clinical development by Accord Healthcare and currently in Pre-Registration for Gastric Cancer. According to GlobalData, Pre-Registration...
Trastuzumab biosimilar by Accord Healthcare for Metastatic Breast Cancer: Likelihood of Approval
Trastuzumab biosimilar is under clinical development by Accord Healthcare and currently in Pre-Registration for Metastatic Breast Cancer. According to GlobalData,...